Epoetin theta biosimilar

Drug Profile

Epoetin theta biosimilar

Alternative Names: Biopoin; Eporatio

Latest Information Update: 06 Feb 2015

Price : $50

At a glance

  • Originator Ratiopharm; Teva Pharmaceutical Industries
  • Developer Teva Pharmaceutical Industries
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 06 Feb 2015 Launched for Anaemia in United Kingdom, Austria, France, Germany, Hungary, Ireland, Netherlands, Poland, Portugal, Czech Republic, Sweden, Spain and Israel (SC) prior to February 2015
  • 06 Feb 2015 Launched for Anaemia in United Kingdom, Austria, France, Germany, Hungary, Ireland, Netherlands, Poland, Portugal, Czech Republic, Sweden, Spain and Israel (IV) prior to February 2015
  • 29 Oct 2009 Registered for Anaemia in European Union, Norway, Switzerland and Iceland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top